Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fingolimod/tofacitinib - VYNE therapeutics

Next Previous
Drug Profile

Fingolimod/tofacitinib - VYNE therapeutics

Alternative Names: FMX-114

Latest Information Update: 03 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VYNE Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Ethanolamines; Eye disorder therapies; Immunotherapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Propylene glycols; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Filaggrin protein stimulants; Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors; Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis

Most Recent Events

  • 03 Apr 2023 VYNE Therapeutics has various patents pending for fingolimod/tofacitinib worldwide which will expire in 2040, 2041 and 2043
  • 09 Mar 2023 Fingolimod/tofacitinib - VYNE therapeutics is available for licensing as of 09 Mar 2023. https://vynetherapeutics.com/
  • 01 Mar 2023 VYNE Therapeutics plans IIb trial in Atopic dermatitis (VYNE Therapeutics pipeline, February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top